APA (7th ed.) Citation

Liu, Y., Wang, W., Yin, R., Zhang, Y., Zhang, Y., Zhang, K., . . . Li, H. (2023). A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: Efficacy, safety, pharmacokinetics and germline BRCA mutation analysis. BMC Medicine, 21(1), 1. https://doi.org/10.1186/s12916-023-03046-8

Chicago Style (17th ed.) Citation

Liu, Yaxin, et al. "A Phase 1 Trial of Fuzuloparib in Combination with Apatinib for Advanced Ovarian and Triple-negative Breast Cancer: Efficacy, Safety, Pharmacokinetics and Germline BRCA Mutation Analysis." BMC Medicine 21, no. 1 (2023): 1. https://doi.org/10.1186/s12916-023-03046-8.

MLA (9th ed.) Citation

Liu, Yaxin, et al. "A Phase 1 Trial of Fuzuloparib in Combination with Apatinib for Advanced Ovarian and Triple-negative Breast Cancer: Efficacy, Safety, Pharmacokinetics and Germline BRCA Mutation Analysis." BMC Medicine, vol. 21, no. 1, 2023, p. 1, https://doi.org/10.1186/s12916-023-03046-8.